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Nutrition plays a crucial role in the development and progression of different types of cancer. 
Dietary components, as well as gut microbiota-derived factors, can exert metabolic and 
immunomodulatory functions on the host, both locally and systemically. Recent studies 
highlighted the role of specific gut microbes as predictors of response to immunotherapy. 
Autophagy has a key function in the elicitation of an immune in response to anticancer therapy. 
Here, we conducted an automatized fluorescent biosensor-based screening to identify 
autophagy modulators from a chemical library of host- and bacteria-derived metabolites and 
found prodigiosin, a red pigment produced by Serratia marcescens, as a potent inducer of LC3 
dots in GFP-LC3 biosensor cells. Further autophagic flux analysis in RFP-GFP-LC3 tandem 
reporter cells and a GFP-Q74 Huntington’s disease model revealed that prodigiosin acts as an 
inhibitor of autophagic flux. Consistent with the described immunosuppressive role of 
prodigiosin, our in vivo experiment in BALB/c mice transplanted with syngeneic colon cancers 
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Nutrition plays a crucial role in the development and progression of different types of cancer. 
1 2 Some diet nutrients, as well as gut microbiota-derived compounds, can exert metabolic and 
immunomodulatory function on the host, both locally on the gut epithelium and systemically.   
Moreover, fasting and caloric restriction reduce side effects and improve the outcome of 
conventional anticancer treatment in preclinical studies. 3 Caloric restriction mimetics (CRM) 
are non-toxic compounds capable of inducing autophagy by decreasing global protein 
acetylation. These molecules mimic the cellular biochemical changes induced by caloric 
deprivation. 4 Experimental studies have highlighted the ability of CRM to stimulate or restore 
anticancer surveillance, crucial for the durable success of antineoplastic therapy. 5 6  
In parallel, some chemotherapy drugs, such as anthracycline or oxaliplatin, possess "bystander" 
effects, namely, they are able, beyond their main mechanism of action, to induce immunogenic 
cell death (ICD) and consequently stimulate an immune response towards residual tumor cells. 
This kind of cell death is characterized by pre-mortem cellular stress that leads to the 
immunostimulatory emission of danger-associated molecular patterns (DAMP). 7 8 Given these 
premises, the main goal of the project was to detect potential new CRMs, ICD inducers, or 
autophagy disruptors from a library of bacteria and host derived metabolites with the purpose 
to identify potential modulator or inductor of response to immunotherapies or other 




1.2. Autophagy modulators and lysosomotropic agents 
 
Autophagy (from the Greek αὐτόφαγος meaning “eating of self”) is a stress-induced 
intracellular machinery through which the cell adjusts its energy requirement and remove 
damaged molecules and organelles or potential intracellular threats. 9 More simplistically, it 
could be also described as a diversified trafficking intracellular system capable of sequestrate 
unrequested molecules into double-membrane surrounded vesicles and vehiculate them to the 
lysosomes for degradation. 10 Since its discovery 11 and its genetic and molecular 
characterization in yeasts 12, this process gains attention due to the potential impact on the 
etiopathogenesis of diseases and drug discovery. Autophagy has been recognized as a leading 
driver or cofactor in several pathological conditions including metabolic or neurodegenerative 
disorders, infectious diseases and cancer. 13 To date three distinctive forms of autophagy have 
been recognized in mammalian cells, according to the lysosome/vacuole membrane onset and 
cargo takeover: chaperone-mediated autophagy, microautophagy, and macroautophagy. 14 15 
These three processes morphologically differ on the modality of cargo sequestration. 16  Here 
we focus mainly on macroautophagy, herein cited as autophagy, which is the most widely 
known and examined pathway. This cellular mechanism consists in the formation of double-
layer membrane vacuoles (autophagosomes) which restrict cytosolic portions, or damaged 
structures, and later vehiculate the cargo to the lysosomes, thus allowing the degradation of the 
cargo mediated by the lysosome hydrolases. 17 
The whole process figuratively consists of five consecutive steps orchestrated by specialized 
autophagy-related protein (ATG): initiation; phagophore constitution by double-membrane 
nucleation; autophagosome generation by phagophore expansion and cargo acquisition; 
autolysosome genesis by fusion with the lysosome; degradation of cargo. 18  Autophagy can be 
either defined as selective or non-selective depending on whether it concerns a clear-cut 
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organelle/microorganisms (e.g. mitophagy or xenophagy, respectively) or not. 19Autophagy-
deficient eukaryotic cells and autophagy-incompetent mice are more sensitive to metabolic 
stressors and more easily develop chemically or genetically induced neoplasms respectively.20 
21 This whole evolutionary-preserved catabolic machinery lies on the concerted activity of 
specialized proteins named ATG (autophagy-related) and it is finely modulated by several 
signaling pathways. 22 In balanced cellular conditions autophagy is enabled at a basal level thus 
preserving the cellular homeostasis. 23 The occurrence of stressors upregulates its activation 
status. The principal inductors of autophagy are nutrient deprivation and cellular metabolic 
perturbations. Nevertheless, some both synthetic and natural pharmacological compounds can 
mimic the biochemical and molecular intra-cellular modification induced by nutrient 
deprivation, thus inducing the autophagic route. This evolutionary preserved machinery is 
finally regulated by a highly interconnected signal transduction cascade. 17 In both mammalian 
and yeast cells, many metabolic sensors (AMPK, mTORC1, eIF2α	  kinases, sirtuins, 
actetyltransferases, transcription factors, and cell surface receptors) and at least two signaling 
pathways sense nutrient availability: PI3K Class III/Akt/mTOR/p70S6K and the 
Ras/Raf/MEK/ERK1/2. 24252617 They mainly act by sensing the accessibility to amino acids, 
glucose, and ATP cellular reservoir. Nevertheless, the accumulation of metabolic subproducts, 
such as ammonia, can stimulate autophagy. 27  
Mechanistic target of rapamycin (mTOR) is the key regulator of autophagy and by and large 
of the homeostasis between catabolic and anabolic processes. 28 mTOR aggregates in two 
complex mTORC1 and mTORC2, but solely mTORC1 is sensitive to cellular nutrient and 
energetic amount. 29 Mechanistic target of rapamycin complex 1 (mTORC1) acts by inhibiting 
autophagy and it can be in turn inhibited by AMP-activated protein kinase (AMPK), which is 
responsive to cAMP increase as a direct result of a higher ATP expenditure. 30 mTORC1 and 
AMPK therefore constitute a regulatory entangled interface which modulates autophagy 
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activation. 29 Several growth factor singling pathways and anabolic inputs inhibit autophagy 
via mTORC1 activation. 31 In nutrient-rich conditions mTORC1 can directly phosphorylate the 
ULK complex (ULK1/2, Atg 13, FIP200) thus inhibiting its kinase activity and blocking 
autophagy. 14 Furthermore, mTORC1 regulates the activation of concurrent signaling pathways 
which in turn modulate autophagy. 24 Amino acid starvation leads to mTORC1 activation and 
autophagosome appearance. 32 Glucose or oxygen deprivation can lead to intracellular 
AMP/ATP ratio increase and AMP-dependent AMPK activation by phosphorylation at Thr-
172, ultimately stimulating autophagy. 33 The AMPK phosphorylation is mainly regulated by 
upstream kinases such as the liver kinase B1 (LKB1) serine/threonine kinase complex (a 
germline mutation of the tumor-suppressor STK11/LKB1 gene occurs in the Peutz-Jeghers 
familial cancer syndrome34) and Ca2+/calmodulin-activated protein kinases. 35 33 36 Metabolic 
disruptor or reactive oxygen species (ROS) can also induce AMPK activation. ROS can both 
act by impairing the ATP generation by the mitochondrial respiratory chain and activating the 
cytoplasmatic pool of ATM (Ataxia-Telangiectasia Mutated).  ATM, a PI3K-like kinase, 
probably causes AMPK activation in an LKB1-depended fashion. 33 Nevertheless, AMPK 
stimulation of autophagy is not restricted to mTORC1 inhibition.  AMPK can activate ULK1 
via phosphorylation. This event is normally prevented under nutrient sufficiency conditions by 
mTORC1, as well as subunits of the BECN1/VPS34 complex. 37 38 Worthy of note is to 
mention that the modifications of intracellular pH, namely mild acidification, can trigger the 
autophagic response. 39 40 Such event typically occurs during starvation and hypoxia. 41 42 Other 
stress stimuli (e.g. protein aggregates, damaged DNA or organelles) can activate autophagy, 
thus giving evidence to its cytoprotective and homeostatic role. 20 
Besides being regulated by metabolic and cellular stress related signals, autophagy is 
additionally controlled by cytokine and other innate immune mediators. 43 Several pathogen-
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associated molecular patterns (PAMPs) can de facto stimulate autophagy via TLR7-MyD88 
pathway. 44 A separate mention goes on intracellular pathogens (discussed below). 
ULK1 (or Atg1) complex, once activated, recruits the PI3K complex thereby contributing to 
the autophagy initiations. 10 Figure Intro (Pag. 22) Phosphatidylinositol 3-phosphate (PIns-
3P) generated by the PI3K complex interact with a pool of protein which possess PIns-3P-
binding motif. These events mediate the autophagosome nucleation. 32 
In yeasts the generation of the autophagosome takes place in specific sites named phagophore 
assembling sites (PAS). The actual source of the isolation membranes is still unclear. 32 In 
mammals, it has been proposed that such an event could occur at designated autophagosome 
formation sites of the ribosome-free region of the ER or Golgi apparatus. 45 46 However other 
intracellular organelles (i.e. mitochondria, endosomes and, plasma membrane) seem to be 
somehow involved and a “de novo” formation of a vacuolar membrane has also been described. 
14 47 At these specific formation sites, the ATG proteins intercede thus enabling the formation 
of the phagophore which later will rip into an autophagosome. 22  IκB kinase (IKK) complex 
which acts by phosphorylating the regulatory subunit of phosphoinositide-3-kinase (PI3K) is 
essential to orchestrate the cellular response to starvation. 48  
After the nucleation, the ATG16L1 complex (composed of ATG5, ATG12, ATG16L1) induces 
the lipidation of LC3, thus allowing its adhesion to the autophagosome membrane. 32 LC3 
lipidation as well as ATG12 conjugation are essential for autophagosome and pre-
autophagosome constitution, respectively.  49 LC3/GABARAP family proteins (LC3, 
GABARAP, GATE-16) are thought to cooperate to the phagophore expansion and constitution 
of an independent membrane-bounded structure.  
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1.2.1 Monitoring autophagy in vitro 
 
Different markers have been proposed to monitor the phenomena “autophagy”. The entire 
process can be outlined in subsequent phases and is mediated by more than 30 autophagy-
related proteins (encoded by ATG genes). Some of those proteins such as Beclin-1, Lamp-1 
and 2 (lysosome-associated membrane proteins), LC3A/B (microtubule-associated proteins 
1A/1B light chains 3A/B) are recognized as appropriate markers for assessing established 
stages of autophagy. The first steps consist of the phagosome initiation, then follow nucleation 
and expansion. Later, the autophagosome fuse with the lysosomes giving rise to the 
autolysosomes. Several methods rely on the evaluation of light chains 3 (LC3). The detection 
of LC3 cytosolic puncta by fluorescence-based microscopy reveals the induction of autophagy. 
50 In light of this an automatized screening platform has been organized for high-throughput 
high-content quantification of pharmacologically induced autophagy in cancer cells. 51 The 
centerpiece of this platform lies in the use of engineered biosensor cells that detect and quantify 
the pharmacological potential of each molecular candidate. Undoubtedly, (GFP)-tagged 
MAP1LC3B/LC3 (microtubule-associated proteins 1 light chain 3 beta) cell lines are by far 
the most used. The lipidation of GFP-LC3, which occurs as part of the autophagosome 
nucleation, allows the detection of morphological modification in the fluorescence pattern 
within the cells. Furthermore, the same model can point out the occurrence of phenotypic signs 
of toxicities, if any. 51 One major limitation resides in the fact that autophagy flux blockers, 
such as lysosomotropic agents, can mimic the fluorescence LC3 pattern induced by genuine 
autophagy stimulators. LC3-II accumulation can be attributable either to the induction of 
autophagy or to a hindrance to the autophagic flux. 52 To further limit the detection of potential 
false-positive subsequent steps are needed. Tandem GFP-RFP LC3 reporter cells are widely 
used to investigate the conversion of the autophagosome into autolysosomes in light of the 
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susceptibility of GFP fluorescence to the decrease in pH. Another option consists in the use of 
cell stably expressing GFP-labelled mutated huntingtin protein. This cell engineering allows 
monitoring the degradation of the autophagic cargo. Furthermore, Western Blotting 
quantification of LC3-I and LC3-II and p62 forms is applied to estimate the LC3 turnover and 
monitor the flux. The cargo receptor protein p62 mentioned above is widely used as an indicator 
of autophagic flux.  Differently from almost all the ATG proteins, the knockout (KO) of p62 
(p62-/-) does not lead to the occurrence of growth retardation and precocious lethality but rather 
mature-onset of obesity in mice. 53 54 Autophagy inhibition led to an increase of p62/SQSTM1 
as the protein is itself degraded by autophagy. 55 Conversely, under conditions of autophagy 
activation a decrease of p62 levels is generally encountered.  
The autophagic process and the lysosomal biogenesis is coordinated by the transcription factor 
EB (TFEB), a master regulator of such cellular catabolic processes. 56 Stable as well as transient 
induced over expression of TFEB induces autophagy in vitro. 56 This transcription factor 
modulates the lysosomal biogenesis by stimulating the of the Coordinated Lysosomal 
Expression and Regulation “CLEAR” network which codify for lysosomal constitutive protein 
and hydrolases as well as components of the vacuolar H+-ATPase. 57 58 TFEB is normally 
present in the cytoplasm in is inactive, phosphorylated forms. 59 TFEB subcellular localization 
is steadily modulated by mTOR-dependent phosphorylation and thus by the nutrient 
availability. 60 In its dephosphorylated status, TFEB relocate to the nucleus where it induces 
the expression of genes involved in lysosomal and autophagy. 61 Through TFEB-GFP 
engineered cell line it is possible to monitor the activation, witnessed by the nuclear 
translocation, of this transcript factor. 62  
Of course, all these in vitro techniques are valuable to detect promising molecules nevertheless 
in vivo testing is mandatory to confirm their activity. The in vivo phase can envisage the use 
 14 
of GFP-LC3 transgenic mouse models as well as the recourse to increasingly specific design 
according to the presumed activity and potential application of the investigated compound. 
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1.2.2. Caloric restriction mimetics (CRMs) 
 
Caloric restriction mimetics (CRMs) are nontoxic metabolites or synthetic chemical 
compounds able to replicate the effect of nutrient deprivation within the cell, thereby eliciting 
autophagy. They mainly act by inducing deacetylases (e.g. resveratrol), inhibiting acetyl 
transferases (e.g. spermidine and curcumin), or depleting acetyl coenzyme A (e.g. 
hydroxycitrate), thus resulting in the deacetylation of cellular proteins. 4 The consequence of 
the protein deacetylation is the up-regulation of the cellular autophagic flux. 51  
The ability of CRMs to induce the metabolic modification induced by starvation makes them 
interesting as anticancer and immune eliciting agents. The beneficial effect of fasting in 
neoplastic disease has been progressively recognized.  The rationale of this approach relies on 
limiting the anabolic demand of the malignant cell, on the induced modification of the cancer 
microenvironment as well as on delaying the onset of chemoresistance and curtailing the 
occurrence of treatment-related side effects.  63 A 48h starvation strategy combined with 
chemotherapy is able to retard the tumor growth in mice.  64 
The use of fasting mimicking diets is one of the potential approaches to overcome the practical 
limitations of a total fasting approach (not feasible in humans as in experimental mouse 
models). Another solution is the identification of non-toxic compounds capable of inducing the 
metabolic effects caused by fasting on cells. The potential benefit of these compounds is not 
restricted to malignant disease but also degenerative age-associated conditions and ischemic 
tissue damages. 65 
The activity of these compounds, which mimic the effects of starvation on cells as well as 
potentially the systemic response to fasting, strongly relies on autophagy induction.  
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The up-regulation of autophagy in dying cancer cells allow the release of eat-me signals in the 
extracellular space, as adenosine triphosphate (ATP), in turn able to attract and promote the 
activity of antigen-presenting cells (APCs). 66 Furthermore, autophagy modulates the exposure 
of CD39, a protein on cellular surface which convert ATP into AMP. This ecto-enzymes is 
strongly induced by several stressors (such as hypoxia and tissue damage and is over expressed 
by various tumor types. 67 
Spermidine, a recognized CRM, is a natural polyamine, such as spermine and putrescine,  
present in all living organisms. 68 69 Furthermore, this compound is also largely produced by 
gut microorganisms. The microbiota composition plays a crucial role in regulating the 
concentration of these metabolites in the colonic lumen and consequently in the bloodstream. 
70 Spermidine and hydroxycitrate, an extract from the fruit Garcinia Cambogia, have shown to 
improve the efficacy of anticancer immunotherapies. 
The administration of hydroxycitrate, spermidine, and alpha-lipoic acid reduces the lung 
implantation of B16 melanoma cells in C57BL/6 mice. 71 Hydroxycitrate acts as inhibitor of 
the ATP citrate lyase. In autophagy proficient mouse models this acidic compound is able to 




1.2.3. Lysosomotropic agents  
 
Lysosomes are acid vesicles (with an interior pH of 4.5-5.0) that figuratively could be described 
as the stomach and the intestine of the cell. These organelles house more than 50 distinctive 
hydrolases able to “digest” all the constituents of the cell. To permit the activity of these 
hydrolases, lysosomes have to generate and preserve an acidic micro-environment. This 
condition is achieved through the intercession of the vacuolar-ATPase proton pumps. 72 The 
V-ATPase pump generates a chemical (pH) and electrical positive potential between the 
lysosome membrane by actively carrying H+ ions within the lysosomal compartment against 
their electrochemical gradient. In the same way as the lysosomes, the interior of most cellular 
organelles exhibits a lower pH than the surrounding cytosol. 73 On the lipidic bilayer the 
electrogenic potential is both dissipated through cation and ClC-7 anion channels which 
mediates the efflux of K+ cation in the cytosol and the influx of chloride anion (Cl-) within the 
lysosome, respectively. 72 This event is crucial to avoid that the electrical potential hinders the 
activity of the pump itself before reaching a target pH. 73 Although not yet fully understood the 
activity of V-ATPase is regulated by intrinsic and extrinsic factors. Bafilomycin A1, an 
inhibitor of V-type H+-ATPase, can impair the lysosomal acidification, thus blocking the 
autophagic flux, and induce a caspase-3 and -9 dependent apoptosis. 74  Furthermore, chloride 
anion (Cl-) is another key regulator of the lysosomal function. Culturing gastric cancer cells 
under Cl- restricted conditions leads to impairment of autophagy (LC3II and p62 accumulation) 
as a consequence of reduced Cl concentration in the cytosol and  the lysosome and concomitant 
increase of intralysosomal pH. 74 Undoubtedly, lysosomes’ cardinal role is to guarantee the 
degradation of misfolded or damaged intracellular constituents as well as the elimination of 
potential treating microorganisms and the regeneration of building blocks for the anabolic 
processes. These organelles further participate in signaling pathways, in the preservation of 
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cellular homeostasis, and the execution of cell death programs.75 The term lysosomotropic, 
according to the definition of C. De Duve, refers to compounds “that are taken up selectively 
into lysosomes, irrespective of their chemical nature or mechanism of uptake”. 76 Many 
pharmacological compounds naturally possess this feature, and if not, it can be obtained by 
coupling them with an appropriate carrier. 76 Such of these compounds are usually weak bases. 
In their active unprotonated status, they can enter within the acidic organelles and accumulate 
as protonated form. They finally lead to an increase in the intra-vesicular pH and a disruption 
of the autophagic functioning. 77 78 Other molecules are also capable to permeabilize the 
phospholipid bilayer that constitutes the lysosomal membrane resulting in an alteration of 
cytosolic pH and release of hydrolytic enzymes. The lysosomal membrane permeabilization 
(LMP) induces the trigger of apoptotic pathway whereas an extensive lysosomal rupture, 
similarly to what happens in case of intestinal perforation in humans, leading to massive 
cellular stress and cell death by necrosis. 79 80 75 It is worthy of note to specify that some 
compounds, e.g. ML.9, can induce the autophagosome formation, in this specific scenario by 
downregulating the Akt/mTOR pathway, while hindering the lysosome degradation by 
increasing the intravacuolar pH. 81 Furthermore, ML-9 was showed to enhance the activity of 
the chemotherapy agent docetaxel by inducing accumulation of autophagic vacuoles and cell 
death in prostatic cancer. 81  
Other agents, such in the case of prodigiosin, can dissipate the lysosomes H+ potential by 
behaving as H+/Cl- symporter. 72 Anion transporters can disrupt autophagy and cause a decrease 
of intracellular pH which in turn can trigger the activation of apoptotic events. 82 83   
Malignant cells elevate autophagy to face the anabolic requests and survive in a hypoxic 
microenvironment. 84 
While lysosomotropic agents are reported to exert anticancer activity in vitro or in 
immunocompromised in vivo models (such as patient-derived xenograft), we speculate that 
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their activity could be counteracting as immunotherapy adjuvant. This assumption relies on the 
fact that the impairment to the autophagic machinery can on the one hand minimize the 
occurrence and the peculiarities of the immunogenic cell death in the cancer cell, on the other 
hand, some compounds could exert the same activities at a similar concentration on specific 
immune cells thus failing in stimulating the mounting of a strong immune response.  
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1.3. Immunogenic cell death 
 
Immunogenic cell death is a peculiar type of cellular demise able to induce inflammatory effect 
and immune modulation in the tissue microenvironment. It is characterized by modification in 
protein on the surface membrane of the dying cell and releasing of immune-stimulating factors 
(DAMPs) in the cell microenvironment. 85 Chemotherapeutic agents such as oxaliplatin and 
anthracyclines can induce ER premortem stress and consequently stimulate the anticancer 
immunoresponse. 86 
 
1.3.1. Main features of ICD 
 
This singular form of cell death is distinguished by a series of pre-apoptotic events: the 
exposure of endoplasmic reticulum (ER) proteins at the cell membrane (mainly calreticulin), 
the release of the nonhistone chromatin protein high-mobility group box 1, (HMGB1) and the 
discharge of ATP in the extracellular space. 85 These happenings suggest the occurrence of 
‘pre-mortem’ cellular distress such as the alteration of ER functioning and induction of 
autophagy. The late phase of this dying process recapitulates the distinctive events which occur 
during the apoptosis (e.g. the exposure of phosphatidylserine (PS) on the cell surface). 87 The 
dying cells expose calreticulin (CRT) on their surface and release ATP and HMGB1 in the 
extracellular matrix. The first of these processes is independent of nuclear activities while 
seems strictly related to reactive oxygen species (ROS) and nitric oxide formation. 85 The ATP 
release, conversely from HMGB1, require an on caspase-dependent activation (accountable for 
specific cleavage of the plasma membrane channel pannexin 1 (PANX1)88) and autophagy 
proper functioning.89 90 Extracellular ATP exerts autocrine and paracrine function. This 
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molecule can interact with purinergic receptors (P2X and P2Y) and is a strong activator signal 
for phagocytes chemotaxis. 89 Furthermore, the systemic administration of these compounds 
reasonably exposes to their effects not only the malignant cells but also the immune cells. 
 
1.3.2. Damage-associated molecular pattern (DAMP) 
 
Damage-associated molecular patterns are both intracellular and extracellular molecules 
released as a consequence of peculiar types of stressors. This group of molecules constitutes 
the “alter ego” of “pathogen-associated molecular patterns” PAMPs and differentiate from the 
latter for their non-infectious origin. Those biomolecules can trigger or sustain an inflammatory 
response in tissues by interacting with a wide class of innate immune receptors collectively 
named pattern recognition receptors (PPRs).91 The pattern recognition hypothesis was 
originally proposed by Charles Janeway who based on the “self/non-self” Burnet’s theory 92 
postulated the existence of recognition receptors on the innate immune cells able to detect 
microbial-derived molecular patterns lately named as PAMPs.93 94 The identification of the 
Toll-Like Receptor (TLR) on the antigen-presenting cells (APC) practically reinforced the 
assumption. The recognition of endogenous host-derived molecules as a potential modulator 
of inflammatory response dates back to the nineties. 95 TLR when triggered by the presence of 
DAMPs or PAMPs act by releasing pro-inflammatory mediators and expressing costimulatory 
molecules which can activate/modulate the adaptive immune response. 96 At present DAMPs 
have been recognized as a major player in initiating and perpetuating the inflammatory 
processes underlying a wide group of diseases such as autoimmune and neurodegenerative 
diseases, metabolic disorders, and lastly cancer. 94 They can be classified according to their 
origin and mode-of-emission. 97 The cellular DAMPs can originate from different 
compartments and organelles (i.e. cytosol, nucleus, mitochondria, endoplasmic reticulum, 
 22 
plasma membrane, and intracellular granules). Furthermore, these molecules can be 
categorized into those exposed on the cellular surface or actively and passively secreted. 
Investigation on new PAMPs, as well as DAMPs released from the host tissues as a 
consequence of bacterial colonization, may offer the opportunity to identify new strategies to 
modulate the immune response in the context of malignant diseases.   
In a similar way, intratumoral bacteria, as well as mucosal-associated microbiota, can both 
impact the metabolic reprogramming of malignant cells and the modulation of the immune 
contexture through the activities of secondary metabolites, toxins, and further mediators. 
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1.4. The human microbiome 
 
In the last decades the historical idea of humans as being simply constituted by eukaryotic cells 
and structured in tissue, organs and, systems has been overtaken by the concept of the ‘Human 
Holobiont’ which flourished notably after the seminal Metchnikoff’s works and had a 
renaissance recently. 98 All in all the human microbiota has been estimated to contain over one 
thousand bacterial species (more than one hundred and sixty in each person) and millions of 
genes. 99 100 Gut microbes are directly involved in energy metabolisms and play a cardinal role 
in modulating the cell-to-cell interaction and host immunity homeostasis.101  
Focusing on oncology, preclinical and clinical findings suggest the crucial role of the gut 
microbiome in shaping anticancer immunity and the response to cancer chemotherapies and 
immunotherapies. 102 103 104 Three recent studies confirmed these data in humans, reporting the 
unexpected role of specific members of the gut microbiota as a predictor of response to 
immunotherapy in a distinctive series of epithelial tumors (NSCLC, renal cell carcinoma, and 
urothelial carcinoma) and melanoma patients. 105 106 107 Moreover, the phenotype of responders 
or non-responders can be transferred by performing fecal microbiota transplantation, such as 
utilizing germ-free or antibiotic-pretreated mice as recipients for feces of responder or non-
responder patients. 108 Similarly, oral supplementation with specific bacteria seems a feasible 
option to restore the phenotype of responders in avatar mice carrying the microbiome of non-
responder patients. 109 In the new era of immunotherapy-based cancer treatments, these pieces 
of evidence are undoubtedly of crucial relevance. The predictive role of the microbiome in 
terms of response and the potential of its manipulation to foster the efficacy of the treatments 
has a large potential for clinical application.  
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1.4.1. Bacterial metabolites or derived secondary metabolites as metabolic and immune 
modulators 
 
Bacteria-derived compounds, both from pathogens and not, can exert a wide range of effect on 
the host. 101 Furthermore, the power of those molecules can be extremely amplified if directly 
released within the tissue. Along these lines, the focus on potential intertumoral bacteria-
derived compounds deserve attention. In the gut lumen, the metabolites can directly derive 
from the diet or conversely be released both from the host cell and the gut microbes. Nutrient 
competition is probably the first discriminant to limit the potential colonization of pathogens.110 
Here I briefly discuss some significant evidence on the most-investigated bacterial metabolites 
and toxins.  
In light of its role in bacterial proliferation, virulence and metabolism iron constitutes one great 
example.111 112 This micronutrient impacts cytokine secretion and transcription of key 
mediators of immune response.111 This mineral is an essential nutrient for both bacteria and 
humans. 113 In mammals, it exerts the most prominent function as a component of oxygen-
carrying proteins myoglobin, and hemoglobin. In addition, iron is required for the function of 
the mitochondrial respiratory chain and DNA synthesis enzymes. Lastly, this metal mediates 
the generation of oxygen radicals in neutrophils and macrophages, and is required for the clonal 
expansion of T cells. 111  Several mechanisms of withholding have evolved to restrict the iron 
availability to intracellular and extracellular microorganisms. 
Others bacterial metabolites or bacterial-processed host compounds can exert specific 
metabolic and immune activities on the host.  
Lipopolysaccharide, a constitutive glycolipid of the Gram-negative bacterial membrane, is able 
to induce inflammatory response through the interaction with different receptors on immune 
cells. LPS activity is mainly mediated by the activation of the TLR-4 cascade and the 
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consequent release of proinflammatory cytokines in the microenvironment. Other proteins, 
namely LPSBP (LPS binding protein) and CD14, facilitate the extraction of LPS monomers 
and the interaction with the TLR4 on the cellular surface. 114 Several studies suggest the pro-
tumorigenic activities of LPS in different types of cancers. 115 116 α-galactosylceramide, and its 
analogs, elicit the activity of invariant natural killer T (iNKT) cells, a distinctive subset of T 
lymphocytes that express an invariant TCRα chain. 117 118  
Bile acids have shown various activities. Among them, deoxycholate (DC) can activate 
autophagy in non-cancer colonic cells by increasing the expression of the autophagic protein, 
beclin-1 in a ROS-dependent manner. 119 DC can also indirectly impact on colonic 
carcinogenesis by activating the COX-2 signaling pathway in the cancer associated fibroblasts. 
120 Lithocholic acid exerts anticancer activities by inducing apoptosis in prostate cancer cell 
line. In such a context, this secondary bile acid has been shown to induce endoplasmic 
reticulum stress as well as autophagy (conversion of LC3BI-LC3BII and ATG5 induction) and 
mitochondrial dysfunction. 121 Ursodeoxycholic acid induces the expression of LC3B in a 
hepatocellular cell line in vitro and in vivo in nude mice. 122 Taurocholic acid, as well as cholic 
and chenodeoxycholic acid, induces LC3B and p62 in primary hepatocytes but this effect 
seems to be attributable to an impairment of the autophagic flux. 123 Glycochenodeoxycholate 
induces autophagy by activating the AMPK/mTOR pathway in hepatocellular carcinoma cells 
and interestingly this effect is reversed by chloroquine (an inhibitor of the autophagic flux). 124 
125 Short Chain Fatty Acids are the  sub-product of bacterial fermentation of non-digestible 
carbohydrates. These compounds can reach high concentration in the blood of the host. 126 
Many of their activities are mediated by the interaction with G-protein-coupled receptors 
(GPRs).  127 Among them butyrate is probably the most characterized. In the colon butyrate is 
able to modulate the inflammatory response by acting both on epithelial cells and immune cells. 
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128 SCFA regulates the function of effector lymphocytes (CD8) as well as the frequency of T-
regs and T cell cytokine release during infections. 129 130 
Indole metabolites, derived from the metabolism of tryptophan, are further relevant mediators 
able to impact on host-immune functions. 131 As an example, indole-3-propionic acid (IPA), 
one of these bacterial produced compounds, exerts anti-inflammatory activities in an in-vivo 
steatohepatitis model by reducing the level of pro inflammatory cytokines via the NF-κB 
signalling. 132 
Finally, a separate mention should be made on bacterial toxins. Pyocyanin, a well-known 
Pseudomonas aeruginosa virulence agent, induces an anti-inflammatory response in LPS-
activated macrophages. 133As proposed by the authors, this may subtend an immune-evasion 
strategy.  Similarly, violacein, a quorum-sensing and water-insoluble compound released from 
Chromobacterium violaceum and other gram-negative bacteria, reduces pro-inflammatory 
cytokine production and induces Tregs in an LPS-induced inflammation model in mice. 134 
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1.4.2. Bacterial interactions with the autophagic machinery 
 
Besides its role as degradation machinery of the cell, autophagy exerts a pivotal role among 
the defenses of the eukaryotic cell against bacteria. This particular type of selective autophagy 
has been named xenophagy by Levine and can advisedly be classified as part of the innate 
immune response. 135 Xenophagy is both essential for the clearance of the intracellular treats 
and the initiation of a pathogen-specific immune response. 136  In this specific autophagic 
process, the cargo identification necessitates a specific interaction between flag molecules (i.e. 
ubiquitin) and specific receptors. Those receptors incorporate the ubiquitin-binding domain 
(UBD) and LC3-interacting region (LIR) motif. The interaction of the LIR region with LC3 
guarantees the recruitment of the phagosome membrane nearby the ubiquitinated pathogens. 
137 The best known and firstly described among those receptors is p62/SQSTM1 (hereafter 
p62). 138 p62 is more widely involved in cargo identification over different forms of autophagy, 
not-only in xenophagy. 55 The function of this adaptor protein has been in-depth detailed in the 
context of protein aggregation diseases. 139 Nonetheless, its role in the recognition of 
intracellular pathogens makes it also a crucial player in innate immunity. 138  To date, many 
other receptors involved in this process have been described: optineurin (OPTN), a neighbor 
of BRCA1 gene 1 (NBR1), and nuclear domain 10 protein 52 (NDP52). 137 In certain 
circumstances the ubiquitination, and then the autophagic process, can be triggered “ab initio” 
by specific inductors such as the S-guanylation of the cysteine of the Group-A streptococcus 
membrane proteins or the galectin-8 depended flagging of endosomal vesicles damaged by 
pathogens (e.g Salmonella, Lysteria or Shigella). 140 141 Furthermore intracellular sensors, 
namely Nod1 and Nod2, are shown to recruit the ATG16L1 at the bacterial entry sites in a NF-
κB/RIP2 independent manner. 142 As an evolutionary consequence, some bacteria developed 
singular strategies to escape the autophagic response. 143 This can be reached through surface 
 28 
modification or production and release of metabolites and mediators. They can act by 
interfering with the signaling pathways that modulate autophagy or directly disrupting the 
autophagic machinery. Certain bacteria species can even modulate autophagy to gain their 
benefit. Some species prevent the fusion of the autophagosome with lysosome thus avoiding 
their degradation and obtaining an intracellular niche to settle down. It is crucial to notice how 
intracellular bacteria evolved singular strategies to modulate autophagy rather than completely 
hinder it. This evidence once again attests to the fundamental importance of autophagy for the 
eukaryotic cell, which constitutes “the casket” for intracellular-bacteria replication. Some 
unique strategies evolved from pathogenic bacteria are discussed below.  
Anaplasma phagocytophilum, an intracellular gram-negative bacterium responsible for human 
granulocytic anaplasmosis, can induce autophagy nucleation and the expression of related 
markers within the host cell (such as LC3-I/II and Beclin 1) while inhibiting the fusion with 
lysosomes. Doing it this way, this microorganism can stably segregate within the 
autophagosome. 144  Similarly, M. tuberculosis, H. pylori, L. pneumophila and M. avium 
prevent through different mechanisms the fusion of autophagosomes with lysosomes. 145 Some 
of them can act by preventing the lysosome acidification while others by disrupting lysosomal 
membrane integrity, as for the virulence factor gamma-glutamyltranspeptidase by H. pylori. 145 
M. tuberculosis ESAT-6 effector protein blocks the process at the stage of phagosome-
lysosome fusion. 146 147  L. pneumophila hijacks the autophagic chain finally leading to the 
genesis of endoplasmic reticulum shaped structures. This gram-negative bacterium induces the 
constitution of singular organelles consisting of smooth vesicles (derived from the ER) that, 
rather than fuse with lysosomes, are later coated with ribosomes. 148 149 Intriguingly, this 
bacterium employs the same trick to hide out in protozoans, which are the primary hosts, 
implying its capability to act on an evolutionarily conserved process. 150 Genetic analysis on L. 
pneumophila mutant strains leads to the identification of dot genes which are required to evade 
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the fusion with lysosomes. 151 Those genes encode for a Dot/icm transporter which shares 
similarities with the bacterial type IV secretion system family, owned by certain other 
microorganisms. 152 Those genes are required for bacterial virulence. 150 The Dot/transporter 
should be involved in the secretion of putative and still unidentified effector molecules that are 
injected into the host cell. 148 Other human pathogens, such as L. monocytogenes and C. 
trachomatis can induce mitophagy consequently increasing the nutrient availability and 
curtailing the production of reactive oxygen species by the invaded cell. 153  Infection by 
Chlamydia, obligate intracellular bacteria, replicate within intracellular vacuoles which do not 
fuse with lysosomes. Chlamydia trachomatis infection induces the formation of LC3 cytosolic 
puncta as well as their colocalization with LAMP1 (a lysosomal marker) however the p62 
cellular amount remains stable or increased. 154 155  Furthermore, Chlamydia trachomatis 
decreases the activity of lysosomal enzyme in macrophages. Intriguingly, the vATPase 
inhibition (by treatment with Bafilomycin A) exerts an opposite effect by stimulating the 
bacterial growth in wild type cell while inhibiting it in ATG5-/- autophagy deficient cells. 155 
These results suggest a dual activity of Chlamydia trachomatis on the autophagic machinery 
and confirm the relevance of the blockage of the autophagic flux in pathogenic model of this 
bacterium. 
L. monocytogenes, a facultative intracellular gram-positive bacterium, can similarly inhibit the 
late autophagic events, thus preventing the degradation of the Listeria-containing phagosomes 
(SLAPs) in the macrophages where it replicates. 156 This event is mediated by the Listeriolysin 
O, a pore-forming toxin that impedes the evolving of vacuoles into autophagosomes and 
maintains the intravacuolar pH as neutral. 157   
Given its ability to generate intracellular niches where replicate, S. typhimurium represents 
another well-described model of intracellular infection by pathogens. In order to survive within 
the phagosomal compartment this bacterium can adapt its metabolism to the extravesicular 
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conditions. 158 Similarly to L. monocytogenes, the effect of this gram-negative bacterium on 
autophagy is ambivalent. S. typhimurium can both induce the autophagic machinery via the 
T3SS1-depended release of amino acids form the host cell (and consequent mTORC1 
inhibition) and escape the autophagic degradation through its SseL deubiquitinase. 159 
Furthermore S. enterica impairs the activity of the lysosome that fuse with Salmonella vacuoles 
by reducing the trafficking of hydrolytic enzymes. 160 Shigella flexneri achieves the same goal 
by inducing autophagy by VirG, that binds the ATG5, while escaping it via IcsB secretion that 
interfere with the autophagic machinery. 161  
 
The Gram-negative bacterium Coxiella burnetii, the pathogenic agent of the Q fever, has 
adapted to replicate in the harsh acidic environment of the phagolysosome. 162 This feature 
makes it unique among intracellular bacteria. C. burnetii rather than escape the bactericidal 
environment of phagolysosomes has evolved a pH-depended regulation of its metabolism as a 
singular parasitic strategy. 163 Autophagy induction by starvation and overexpression of 
autophagic proteins fosters the replication of this obligate intracellular gamma-
proteobacterium by promoting the development of replicative compartments. 164 
S. marcescens, another gram-negative, release the ShlA pore-forming exoprotein which can act 
as a potent cytotoxin. Furthermore, this protein can stimulate the autophagic response in 
nonphagocytic cells before the bacterial internalization happens. 165  Bifidobacteria reduce the 
autophagy activation of intestinal epithelial cells induced by lipopolysaccharide from gram-
negative bacteria.166 167   
Other bacteria can act on TFEB which is involved in the host response to the infectious threat.  
In Caenorhabditis elegans, the homolog of TFEB is strongly activated upon Staphylococcus 
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aureus infection. 168 Similarly, Salmonella typhimurium induces TFEB activation in mouse 
macrophages through the activation of the phospholipase C/protein kinase D pathway. 169  
 
Figure Intro 1 
 
 
Figure Intro. Bacterial interactions with the autophagic machinery. ULK initiation complex: ULK1 




1.4.3. Intra-tumoral bacteria 
 
A growing interest is flourishing in the last years on the identification of intra-tumoral bacteria.  
Several research papers are shedding light on the potential implication of intra-tumoral bacteria 
on the response to anticancer treatments. 170 Geller et all. recently reported that intratumor 
microbes can impact the efficacy of anticancer therapies. The authors showed that intratumor 
Gammaproteobacteria which possesses the bacterial enzyme cytidine deaminase can convert 
gemcitabine into its inactive metabolite. Furthermore, they reported that more than 70% of 
pancreatic ductal cancer they screened were positive for bacteria (mainly 
Gammaproteobacteria). 170 
More recently a deeper characterization of the tumor proper microbiome in comparison with 
the adjacent non-tumoral tissue has been carried out as regards seven types of common cancers 
(breast, lung, ovary, pancreas, melanoma, bone, and brain). 171 The authors reported both 
malignant and tumor-infiltrating immune cells can host bacteria. 171 Furthermore, the 
composition of the tumor microbiome, as well as its plausible metabolic function, 
quantitatively and qualitatively vary across different tumor types and even subtypes (as for 
breast tumors). 171 The origin of this microbial tissue ecosystem is still unclear although the 
leaky tumoral vasculature and the tumor inflammatory microenvironment could play a crucial 
role. 171 172 
This evidence does not allow to assert a metabolic dependency or a “symbiotic relationship” 
between bacteria and tumoral cells yet, but it opens to further investigations. Furthermore, the 
bacterial composition may impact the response to anti-cancer treatments, particularly 
immunotherapies, as well as provide an opportunity to identify peculiar tumor metabolic 
dependencies. It is also worthy of note that being a low biomass microbiome still makes it 
challenging to dissect at the species level. 173 
 33 
In addition to the potential use in the diagnostic field, the more innovative perspective lies in 
the preclinical development of engineered tumor-targeting bacteria. 174 175 Some bacteria 
species can constitutively exert antitumor activities (e.g. Salmonella Typhimurium). 176 A 
detailed portray of tumor colonizing microbiota can also lead to the selection of ideal strains to 
deliver active compounds and pro-drug converting enzymes or able to foster immune-related 
reactions against cancer cells. In this context, the selective tumor trophism of systemic 
administered bacteria constitutes one crucial aspect. 177 178 To date many details of preferential 
tumor colonization by specific bacteria remains unclear. Bacterial metabolic properties could 
play a pivotal role. As an example, the disruption of the aromatic amino acid biosynthetic 
pathway, widely used to obtain e virulence attenuated bacterial strains, led to relevant changes 
in bacterial colonization of tumors in mice. 179 Another possible strategy relies on the use of 
activable synthetic metabolites (e.g. by light irradiation) to maximize the on-target efficiency. 
180 Furthermore, the intratumor bacteria are probably closely interrelated with gut microbiota 
composition. 181 This evidence could strengthen the significance and hide a potential role of 
gut dysbiosis in several steps of cancer development and treatment.   
Recently, some pieces of evidence on the potentiality of those approaches are increasingly 
coming out. A research team reported the feasibility and the efficiency of radioactive Listeria-
32P strain in vitro and KPC mice. 182 Another team reported encouraging both in terms of 
efficacy and toxicity data by combining live-attenuated Listeria monocytogenes with GM-
CSF–secreting allogeneic pancreatic tumor cells in highly pretreated patients. 183 
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1.4.4 Prodigiosin and S. marcescens 
 
Prodigiosines are secondary metabolites produced by many strains of both Gram-negative and 
Gram-positive bacteria (i.e. S. marcescens, V. psychoerythrus, S. rubrireticuli, and other 
eubacteria). 184 These red-pigmented compounds are constituted by a linear methoxytripyrrole 
skeleton. Those molecules are deemed capable of exerting various biological activities among 
which antifungal, antibacterial, antiprotozoal, antimalarial, immunosuppressive, and 
anticancer activities. 185 Due to its chemical structure, prodigiosin can act as a chloride anion 
binder. Each prodigiosin molecule in its protonated form can carry a chloride ion (Cl-) through 
three hydrogen bonds tush behaving as a H+/Cl- symporter. 72 Furthermore the amphiphilic 
nature makes it excellent as a transporter across the lipidic membranes. 72 Its biological function 
remains unclear but some hypotheses have been postulated. 184 It is known for its antimalarial, 
antineoplastic, and antibiotic activity. 186 Prodigiosin and its synthetic analogs Obatoclax have 
been shown an interesting large-spectrum cytotoxic activity in vitro on cancer cells and 
Obatoclax is currently investigated in more than one clinical trial on hematologic diseases.   
The proapoptotic activity of these molecules appears ascribable to induced modification of the 
cytosolic pH (cyt-H) and lysosomal pH (lys-pH).  
Serratia marcescens, a gram-negative bacillus, is an important cause of nosocomial infection. 
187 This saprophytic enterobacterium is quite common in the environment and has been found 
in food, particularly starchy substances. 187 It has been considered non-pathogenic for a long 
time until the report of nosocomial infection in humans and animals began to appear in the 
latter half of the 20th century. 188 189 190 191 S. marcescens has been reported as a microbial agent 
implicated in respiratory and urinary tract infection, as well as septicemia and wound infection. 
192 193 194 195 Furthermore, some reports described infection sustained from prodigiosin 
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producing strains. 196 Another common feature, is that the infection mainly, but not exclusively, 
affects patients with chronic disorders; a condition that earned him the title of opportunistic 
bacterium. A case series showed how Serratia marcescens was detectable in up to 30% of 
specimens obtained through bronchoscope procedures. 197 
Prodigiosin has been accredited with distinctive properties on cells. This toxin can induce 
lysosome de-acidification and consequently cytosolic acidification and apoptosis.72 It acts as a 
chloride anion binder able to convey the Cl- anion across the lysosome bilayer membrane thus 
decoupling the intra-vacuolar H+ ion potential generated by the vacuolar-ATPase proton 
pumps. 72 Based on this assumption we support the hypothesis that these bacterial metabolites 
could facilitate the bacterial settlement within the cell. As an example, recently a new light on 
the veritable function of the Shiga toxin from enterohemorrhagic Escherichia coli (EHEC) has 
been proposed. In the present case, the researchers showed how Shiga toxin was required for 
suppression of inflammasome responses to cytosolic LPS thus impairing the intracellular 
immune response against the bacterium. 198 Along similar lines, probably prodigiosin is a 
molecule released by some bacterial strains to enhance the potential of this bacterium to invade 
the cells and live intracellularly. The activity in alkalinizing the lysosome and the probable 
induction of lysosome genesis should confirm such a theory. Doing that the bacterium can 
create intracellular niches to survive. 199 One plausible explanation of this phenomenon could 
be linked to the antigenicity of the bacterium. Along similar lines, an interesting paper reported 
the tumor-immunotherapeutic efficacy of the S. marcescens extracts. 200 This assumption is 
further supported by the evidence of some activity of the Coley’s toxin, which consists of 
streptococcal and Serratia marcescens extracts, against Bone and Soft-Tissue Sarcomas. 201 
On tumoral cells, it can induce apoptosis in hematopoietic cell lines with no marked toxicity in 
non-tumoral cells. 202 The apoptotic death of B-cell chronic lymphocytic leukemia (B-CLL) 
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cells occurs by reaching an IC50 of 116±25 nM. 203 Prodigiosin showed similar activity on 
colon cancer cell lines. The IC50 was 275 nM in SW-620 cells. 204 
Noteworthy, cycloprodigiosin hydrochloride, uncedylprodigiosin (UP), and prodigiosin exert 
their effects also on immune cells. UP blocks the proliferation of T and B lymphocytes as well 
as the T cell activation at lower concentrations (IC50 7-20 nM) than those required to inhibit 
the proliferation of leukemic cells.205 Conversely from Cyclosporin A, UP activity relies on the 
hindrance to phosphorylation of the retinoblastoma protein (RB) and the inhibition of cell-
cycle genes (cyclin E, cyclin A, cdk2, and cdk4). Those events result in a block of T cell in the 
mid to late G1 phase. Furthermore, other authors showed that prodigiosin can interfere with 
the IL-2/IL-2R signaling pathway by inhibiting IL-2Ralpha expression. In doing so prodigiosin 
impedes the T lymphocytes differentiation both into effector T helper and effector cytotoxic T 




2. The bacterial metabolite prodigiosin inhibits autophagy and suppresses 
antitumor immunity. Results from a fluorescent biosensor-based screening 
of bacterial and host-derived metabolites. 
 
 
2.1. Introduction and aim of the project 
 
During the last few years, the gut microbiota has gained increasing attention as a consequence 
of its emerging role as modulators of the immune system. 208 209 Fascinating studies are 
shedding light on the impact of the gut microbiome in shaping the response to anticancer 
immune treatments. 106 Along similar lines, a growing interest is flourishing in deepen the 
knowledge on the settlement and function of intracellular tumor-specific bacteria.171 
In such a context, our project aimed to screen a library of microbial metabolites by in vitro 
automatized biology approaches to select potential candidates able of acting as autophagy 
modulators and/or ICD inducers, to eventually evaluate their efficacy in combination with 
immunotherapy in vivo.  
More in detail, we performed a further automatized fluorescence-based screening of a list of 
bacterial and host-derived metabolites to identify compounds able to interfere with the 







Appendix table 1 
Name Effect Reference 
Acetate Induces apoptosis in colon rectal cancer cells Oliveira et al., 2015 210 
Butyrate Prevents autophagy in colonocytes Donohoe et al., 2011211 
Propionate Triggers autophagy in colon cancer cells Tang et al., 2011212 
Trimethylamine Scarce available data Falony et al., 2015213 
Trimethylamine N-oxide 
(TMAO) 
Inhibits ATG16L1, LC3-II and p62 expression Yue et al., 2017214 
Dimethylamine Lysosomotropic compound Kuzu et al., 2017215 
Monomethylamine Blocks lysosome acidification Sobota et al., 2009216 
Indole Up-regulates autophagy in Flp-In 293/SH-SY5Y cells 
Lin et al., 2014217 
Indoxyl sulfate Activates the autophagic machinery. Inhibits the autophagic flux 
Sun et al., 2017218 
Rodrigues et al., 2020 219 
L-Leucine Inhibits autophagy. Stimulates mTOR signaling Meijer et al., 2015220 
Isoleucine Isoleucine deprivation activates autophagy Sheen et al., 2011221 
Valine Limited effect Alvers et al., 2009222 
P-cresol Activates the autophagic machinery Sun et al., 2017218 
Phenylacetic acid No activity Peraro et al., 2017223 
Phenylacetyl glutamine 
(PAG) 
anti-inflammatory activity via inhibition of T cell 
activation and Toll-like receptor 4 signaling 
Hazekawa et al., 2018 
224 Nicklin et al., 2009225 
Indoleacetic acid Inhibits the autophagic flux Rodrigues et al., 2020219 
Tryptamine Induces cell death with ultrastructural features of autophagy 
Herrera et al., 2006226 
α-galactosylceramide Invariant natural killer T (iNKT) cells activation Keller et al., 2017117 
Linaclotide Selective guanylate cyclase C agonist. Analgesic activity on irritable bowel syndrome (IBS) 
Castro et al., 2013227 
Deoxycholic acid Activates autophagy in non-cancer colonic cells. Increased ROS-dependent expression of beclin-1 
 Payne et al., 2009119 
Lithocholic acid Induces autophagy, ER stress and mitochondrial dysfunction in prostate cancer cell line 
 Gafar et al., 2016121 
Ursodeoxycholic acid Induce LC3B in hepatocellular carcinoma cell line and in nude mice 
 Wang et al., 2017122 
Nor-ursodeoxycholic acid Moderate increase in hepatic autophagy and antiapoptotic effects 
Tang et al., 2016228 
Taurocholic acid Increases LC3II and p62 in hepatocyte by impairing autophagosomal-lysosomal fusion 
Manley et al., 2015123  
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Glycochenodeoxycholate Induces autophagy by the AMPK/mTOR pathway in HCC cells 
 Gao et al., 2019124 
Benzoic acid Inhibits autophagy by intracellular acidification and disrupting the membrane trafficking 
Hazan et al., 2004229 
Hippuric acid Scarce available data   
Succinate Scarce available data   
Urolithin A Elevates the autophagic flux in macrophages Boakye et al., 2018230 
Kynurenic acid Induces the production of IL-6 Van der Leek et al., 2017231 
Kynurenin 
Inhibits autophagy in bone marrow 
mesenchymal stem cells (LC3B-II and 
autophagolysosomal reduction/p62 increase) 
 Kondrikov et al., 
2020232 
Anthranilic acid  Scarce available data   
Quinolinic acid Induces the expression of damage-regulated autophagy modulator, beclin 1, and LC3-II 
 Wang et al., 2009233  
Serotonin Induces autophagy in an AKT/mTOR independent fashion in liver cancer cell line 
 Niture et al., 2018234 
Melatonin Enhances autophagy response via SIRT1 deacetylation 
 Nopparat et al., 2017235 
Indolepiruvic acid (IPA) Scarce available data   
Nicotinic acid 
Nicotinic Acid Adenine Dinucleotide Phosphate 
(NAADP) increases levels of LC3II, beclin-1 
and acidic vesicular organelles in astrocytes 
 Pereira et al., 2011236 
2-picolinic acid (PA) Scarce available data   
N-methyl-d-aspartate 
(NMDA) 
Induces autophagosomes accumulation and 
autophagic death in rat organotypic hippocampal 
slices 
 Borsello et al., 2003237 
3-hydroxykynurenine (3-
HK) 
Scarce available data   
3-hydroxyanthranilic acid 
(3-HAA) 
Scarce available data   
GYY4137 Hydrogen sulfide (H2S) induces autophagy via AMPK pathway in colon cancer cell lines 
 Wu et al., 2012238 
Taurine 
Induces autophagy in adipocytes via TFEB 
nuclear translocation. Induces autophagy in 
Leyding cells.  
Kaneko et al., 2018239 
Yahyavy et al., 2020240 
Valeric acid 
Modulation of the autophagic machinery by 
activation of mTOR pathway in Parkinson’s 
disease rat model. 
 Jayaraj et al., 2020241 
1-methylnicotinamide 
The related enzyme, Nicotinamide N-methyl 
transferase (NNMT), negatively regulates 
autophagy 
 Shin et al., 2018242 
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Dopamine Induces autophagy (LC3-II activation) and exerts toxic effect on neuroblastoma cells 




GABAergic signaling promotes antibacterial 
autophagy 
Kim et al., 2018244 
3-hydroxybutyrate (beta-
hydroxybutyrate) 
Stimulates the autophagic flux in cortical 
neurons cultured under glucose deprivation 




IPA suppresses NF-κB signaling and decreases 
the release of proinflammatory cytokines in a rat 
model of high-fat diet 
 Zhao et al., 2019246 
Violacein Impairs the autophagic process in RAS- and RAF-mutated melanoma cells 








Scarce available data   
3,4-dihydroxymandelic 
acid (DHMA) 
Scarce available data   
GG-lysine L-Lysine stimulates Akt/mTOR and inhibits Autophagic Proteolysis  
 Sato et al., 2015 248 
Ferulic acid Activates basal autophagy by inhibiting mTOR (TORC1) in mouse primary hepatocytes 
 Bian et al. 2013249 
Vitamin B1 (thiamine) 
Thiamine deficit induces up-regulation of 
autophagic markers (LC3-II, Beclin1, Atg5) and 
autophagosome accumulation 
 Meng et al., 2013250  
Vitamin B2 (riboflavin) Scarce available data   
Vitamin B3 
(nicotinamide) 
SIRT1-dependent induction of autophagy and 
modulation of mTOR pathways 
 Maiese, 2020251 
Vitamin B5 (pantothenic 
acid) 
Vit B5 is an obligatory precursor of acetyl-CoA. 
Depletion of acetyl-CoA induces autophagy 
 Mariño et al. 2014252 
Vitamin B6 (pyridoxine) Pyridoxine improves the immunogenicity of cisplatin-induced ICD (mechanism still unclear)  
 Aranda et al., 2014253 
Vitamin B6 (pyridoxal) Pyridoxine improves the immunogenicity of cisplatin-induced ICD (mechanism still unclear)  
 Aranda et al., 2014253 
Vitamin B6 
(pyridoxamine) 
Pyridoxine improves the immunogenicity of 
cisplatin-induced ICD (mechanism still unclear)  
 Aranda et al., 2014253 
Vitamin B7 (biotin) Inhibits autophagy and elicits endoplasmic reticulum stress in adipocytes 
 Selvam et al., 2019254 
Vitamin B9 (folic acid) 
FA deficiency induces autophagy enhancement 
(autophagosome accumulation and LC3 and 
Beclin1 overexpression) in neuronal cells 
 Zhao et al., 2016255 
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Vitamin B12 (cobalamin) Vit B12 and FA prevent autophagic inhibition induced by hyperhomocysteinemia 
 Tripathi et al., 2016256 
Sarcosine Activates autophagy and enhances the autophagic flux in cultured cells 
 Walters et al. 2018257 
Equol 
Seems to reverse the effects of zearalenone 
(among which there is an autophagy induction) 
on ovarian preantral follicles  
 Silva et al., 2019258 
Prodigiosin Inhibits autophagy and induces apoptosis of K562 leukemia cell line 
 Ji et al., 2019259 
Phenazine-1-carboxylic 
acid 
Impairs vesicular trafficking and autophagy in 
Saccharomyces cerevisiae 
 Zhu et al., 2017260 
Pyocyanin Induces autophagy by EIF2AK4/GCN2 pathway in Beas-2B cells 
 Yang et al., 2016261 
1-hydroxyphenazine 
Inhibition of autophagy protects astrocytoma 
cells against 1-hydroxyphenazine induced 
toxicity 




Induces oxidative stress and apoptosis in murine 
skeletal muscle 
 Bandyopadhaya et al., 
2016263 
1,4-dihydroxy-2-
naphthoic acid (DHNA) 
Scarce available data   
O-desmethylangolensin 
(ODMA) 
Scarce available data   
Cyclic-di-AMP sodium 
salt 
The cytosolic DNA sensor, cyclic GMP-AMP 
synthase, promotes the autophagic targeting of 
M. tuberculosis 
 Waston et al., 2015264 
5-hydroxy-L-tryptophan Serotonin has been hypothesized to inhibits autophagy thus enhancing gut inflammation 
 Haq et al., 2019265 
5-hydroxyindole acetic 
acid (5HIAA) 
Induces apoptotic cell death of prostate and 
bladder cancer 
 Jeong et al., 2011266 
Indole-3-butyric acid It is converted to indole 3-acetic acid in a peroxisomal β-oxidation process 
Damodaran et al., 
2019267 
Queuine Scarce available data   
L-(+)-Ergothioneine Antioxidant cryoprotection  Paul and Snyder, 2010268 
Pyrroloquinoline quinone Protects cell from autophagy-dependent doxorubicin-induced apoptosis 
 Jiang et al., 2019269 
GG-leucine 
Amino acids are feedback inhibitors of 
autophagy. Leucine acts in a GLUD1-dependent 
fashion 
 Lorin et al., 2013270 
GG-tryptophan Induces mTOR activation  Osawa et al., 2011271 
GG-tyrosine Inhibits autophagy   Meijer et al.,2015220 
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Sodium hydrosulfide Suppress overactivated autophagy in an ischemia/reperfusion model in rats 
 Jiang et al., 2017272 
Rapamycin Inhibits mTOR. Induces autophagy  Sarkar et al. 2008273 
Torin-1 Inhibits mTOR. Induces autophagy  Zhou et al., 2013274 
Thapsigargin Induces ER stress  Li et al., 2000275 
Tunicamycin Induces ER stress  Zhang et al., 2014276 
Brefeldin A Reversibly disrupts the Golgi apparatus  Sciaky et al., 1997277 
Crizotinib R Induces autophagy and immunogenic cell death You et al., 2015
278 
Liu et al., 2019279 
Spermidine Induces autophagy  Eisenberg et al., 2009280 
 
Appendix Table 1. All bacterial metabolites screened with one ref. for each of them (name, effect, 



















2.2.1 Screening program 
 
We determined the maximum solubility known for each compound (or 200 mM if the 
maximum solubility exceeded this value) and prepared the stock solution by diluting them in 
DMSO (mostly) or water. We firstly organized a mother 96-wells master plate with our 
compounds and controls. Subsequently we treated GFP-LC3 U2OS cells in 384 well plates at 
different dilutions (1/300*; 1/1000; 1/3000; 1/10000; 1:30000; 1:100000; 1:300000; 
1:1000000*; * the first and last dilution only when indicate according to the compound 
concentration in the master plate). Suppl. Fig. 1.   










Mother master plate (max solubility or if >200 mM -> 200mM) 
96 well master plate
(84 compounds + Ctrs) 
1 2 3 4 5 6 7 8 9 10 11 12
A n1 n2 n3 n4 n5 n6 n7 n8 n9 n10 n11 n12
B n13 n14 n15 n16 n17 n18 n19 n20 n21 n22 n23 n24
C n25 n26 n27 n28 n29 n30 n31 n32 n33 n34 n35 n36
D n37 n38 n39 n40 n41 n42 n43 n44 n45 n46 n47 n48
E n49 n50 n51 n52 n53 n54 n55 n56 n57 n58 n59 n60
F n61 n62 n63 n64 n65 n66 n67 n68 n69 n70 n71 n72
G n73 n74 n75 n76 n77 n78 n79 n80 n81 n82 n83 n84
H n85 n86 Rapamycin Torin1 Thapsigargin Tunicamycin Brefeldin A Crizotinib R Ctr MEDIUM Ctr H2O Ctr DMSO Ctr
384 well treatment plate
(84 compounds + Ctrs) 
Different timepoints 
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Supplementary Figure 1. Scheme of the design of the screening. Cell death essay (Hoechst/PI) and 
LC3 dots essay by treating U2OS wt and U2OS L3-GFP cells, respectively with a wide range of 
dilutions of the mother stock (1/300*, 1/1000, 1/3000, 1/10000, 1/30000, 1/100000, 1/300000, 
1/1000000*). *only when indicate according to the compound concentration in the master plate 
 
 
2.2.1 Cell lines and culture conditions 
 
U2OS wild-type cells and their derivatives (U2OS LC3-GFP; U2OS LAMP-GFP; U2OS 
GALT-GFP, U2OS SMAC-GFP; U2OS Calr-GFP H2B-RFP; U2OS TFEB-GFP) were 
cultured in DMEM supplemented with supplemented with 10% heat-inactivated fetal bovine 
serum and 10 mM HEPES buffers. PC12 GFP-Q74 cells were cultured in RPMI‐1640 
containing 5% fetal bovine serum and 10% horse serum. Murine colon carcinoma CT26 cells 
were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine 
serum, 10 mM HEPES buffers, 10 U/ml penicillin sodium and 10μg/ml streptomycin sulfate. 
PC12 cells stably expressing doxycycline-inducible Q74-GFP were maintained in (RPMI)-
1640 containing 5% fetal bovine serum and 10% horse serum. 281 
 
2.2.2 Automatized fluorescent biosensor-based screening 
 
Human osteosarcoma U2OS cells stably expressing green fluorescent protein (GFP)-tagged 
LC-3 were seeded in 384-well black microplates (Greiner-bio-one, Kremsmünster, Austria) 
and allowed to attach for 24 h (37 °C, 5% CO2 atmosphere). After 24h the cells were treated 
with the compounds of a custom arrayed library of microbial compounds at different 
concentrations and for different durations. After treatment cells were fixed with 4% 
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paraformaldehyde (PFA) in PBS containing 2µM (10μg/mL) Hoechst 33342 (Thermo 
Scientific, Waltham, MA, USA) for 30 minutes and washed three times with PBS. Four view 
fields/well were acquired by ImageXpress automated widefield microscope (Molecular 
Devices, Sunnyvale, CA, USA). High-content image analysis was used to determine markers 
of autophagy such as the generation of autophagy-associated GFP-LC3 puncta in the 
cytoplasm. Following images were processed and segmented with the MetaXpress software 
(Molecular Devices) to analyze GFP-LC3 granularity. Data were analyzed using the freely 
available software R (https://www.r-project.org).  
 
2.2.3 Cell death essay 
 
U2OS wild-type cells were seeded (2,000 cells/well) in 384-well clear cell culture plates and 
let adhere in a humidified incubator with 5% CO2 at 37°C for 24 h before treatment. Cells were 
treated with a wide range of concentrations for each compound for 24 h and then co-stained by 
the addition of 1μg/ml propidium iodide (PI) and 2μg/ml Hoechst 33342 for 30 min at 37°C 
before acquisition. Images were acquired on ImageXpress Micro XL automated microscopes 
(4 view fields per well). Before being acquired the plates were centrifuged in order to drive 
detached cells to the bottom of the wells. If the cell nucleus was stained by both Hoechst and 
PI signals (fluorescence co-localization), the cell was considered as dead. 282 
 
2.2.4 Autophagic flux analysis  
 
The autophagic flux analysis was conducted by using the U2OS GFP‐RFP-LC3 tandem 
reporter cells and PC12 GFP-Q74 cells. 
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U2OS cells stably expressing LC3 fused with tandem fluorescent GFP‐RFP proteins (GFP‐
RFP‐LC3) were treated with top hits compounds that emerged from the first and second 
screening, for 6 h. After fixation, GFP‐LC3 and RFP‐LC3 dots were evaluated by automated 
image acquisition and analysis. 
The PC12 GFP-Q74 cell is a cell line engineered to express a doxycycline-inducible autophagic 
cargo (namely a pathogenic huntingtin protein that contains 74 glutamine repeats, Q74, fused 
with GFP). 281 Different concentrations of our compounds were evaluated. Rapamycin 
(20 μM), Torin-1 (0.3 μM) and Bafilomycin (0.1 μM) were utilized as controls.  




U2OS WT cells were treated with the different concentrations of our compound for 6 hours. 
Then, cells were washed twice with cold phosphate-buffered saline (PBS) and then dislodged 
by using a cell scraper and collected into microcentrifuge tubes. After centrifugation the lysis 
buffer with protease inhibitor cocktail was added and the cells were incubated for 30 minutes 
on ice followed. After removal of insoluble material by centrifugation, the supernatant was 
transferred into a new tube and the concentration of protein was assessed by using a 
spectrophotometer. For each sample, 20 µg of protein was resolved on polyacrylamide gel 
electrophoresis gel (Invitrogen). After migration protein were transferred to polyvinylidene 
difluoride membranes (Merck Millipore). LC3 and p62 protein levels were measured by SDS–
PAGE and immunoblot. Beta-actin was measured as loading control. Band intensities of p62, 
LC3‐I, and LC3‐II were measured, and ratios of p62 or LC3‐II vs. Beta-actin. (LC3‐II/Actin, 
p62/Actin) were calculated. 
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2.2.5 TFEB translocation and cotreatments with protein synthesis inhibition or lysosome 
inhibitors in vitro 
 
U2OS cells stably expressing GFP‐TFEB fusion protein were treated with different 
concentrations of our compound for 6 h. GFP intensities in nuclei and cytoplasm were 
measured. The ratio of GFP intensities (intensity in nuclei/intensity in the cytoplasm) was 
estimated to assess TFEB translocation into the nuclei. 
We further evaluated the ability of our compound to still induce LC3-II in the presence of 
transcription or protein synthesis inhibitors (with actinomycin D or cycloheximide) and 
inhibitor of the lysosomal proton pump (Bafilomycin) in vitro. 
2.5 × 103 U2OS-GFP-LC3 cells/well were plated in a 384 well plate and cotreated (after 24h) 
with our selected compound in combination with 1 μM dactinomycin (DACT), 50 μg ml−1 
cycloheximide (CHX) and Bafilomycin (0.1 μM) respectively, for 6 h. After fixation, GFP‐
LC3 dots were evaluated by automated image acquisition and analysis. 
 
2.2.6 Co-localization experiment: 
 
Prodigiosin is well-known for its autofluorescence. Prodigiosin signal was measured at an 
excitation of 561 nm and an emission of 594 nm (Texas Red). Briefly, for the co-localization 
experiment human osteosarcoma U2OS biosensors cells expressing the fluorescent fusion 
GALT1-GFP (for the Golgi apparatus), CALR-GFP/H2B-RFP (for the ER), LAMP1-GFP (for 
the lysosomes) and SMAC-GFP (for the mitochondria) were plated on 384-well black 
microplates (Greiner-bio-one, Kremsmünster, Austria).  Image segmentation and 
colocalization of auto-fluorescent compounds with the above-mentioned organelles were 
performed by the ColocalizR analysis algorithm. 283 
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2.2.7 In vivo experiment 
 
Syngeneic BALB/c female mice were implanted with CT26 mouse colon cancer cell line. Mice 
were used between 6 and 8 weeks of age. 1 × 106 CT26 cells were mixed with 100 μL PBS and 
injected subcutaneously into one flank. Once visible, tumors were measured across two 
diameters, and volumes were calculated. Body weights were also recorded. When tumors 
reached 20 to 35 mm² in size mice were treated according the scheme reported in Figure 6a 
with isotype control, clone 2A3, plus prodigiosin vehicle (controls); anti-PD-1 mAb 
(250µg/mouse; clone RMP1-14) plus vehicle; Prodigiosin plus isotype control; Prodigiosin 
plus anti-PD-1 mAb; anti-PD1 plus anti-CTLA-4 (100µg of anti-CTLA-4 mAb (clone 9D9). 
The size of the tumor was monitored after three days from the treatment by means of a caliper 
and mice were then sacrificed. The tumor size was calculated as: length(mm) x width(mm) = 
tumor size (mm2). The heart, the liver, the spleen, the colon, the ileum, and the tumors were 
collected after the sacrifice. 1% DMSO/12%PEG 400 in normal saline was chosen as drug 
delivery vehicle for prodigiosin according to previous report. Firstly 1 mg prodigiosin was 
dissolved in 1 mL of dimethyl sulfoxide in a 20μL DMSO/240μL PEG 400 solution. Then 
1740 normal saline was added to obtain the primary emulsion. 284 A fixed volume of 200μL 
was administered intraperitoneally in each mouse to achieve a dose of 5 mg/kg. Data analyses 
were performed either with the Prism 8 (GraphPad, San Diego, CA, USA) software. Tumor 
size differences were calculated either using two-way analysis of variance (ANOVA) and post 
hoc T-test with Bonferroni Correction (to compare the group treated with Prodigiosin plus 






Unless otherwise specified, data are reported as mean ± SD of at least three independent 
experiments. Data were analyzed using Prism 8 (GraphPad Software, Inc., La Jolla, CA, USA) 
and R software. Statistical significance was analyzed by means of two-tailed Student’s t-test or 
ANOVA tests, as appropriate. Differences to negative controls were assessed to be significant 






























2.3.1 Identification of prodigiosin as a ‘bona fide’ autophagy disruptor 
 
In an effort to identify new autophagy inducers, we initially screened a library of 85 bacterial 
metabolites (Appendix Table 1 in the introduction) for their capacity to stimulate the 
generation of cytoplasmic GFP-LC3 dots in human osteosarcoma U2OS GFP-LC3 cells.  
The screening approach is summarized in Suppl. Fig. 1 (description in the methods 
subsection). 
   
Supplementary Figure1. Scheme of the design of the screening. 
From our first screen we selected the bacterial metabolites that showed the strongest effect. Fig 









Mother master plate (max solubility or if >200 mM -> 200mM) 
96 well master plate
(84 compounds + Ctrs) 
1 2 3 4 5 6 7 8 9 10 11 12
A n1 n2 n3 n4 n5 n6 n7 n8 n9 n10 n11 n12
B n13 n14 n15 n16 n17 n18 n19 n20 n21 n22 n23 n24
C n25 n26 n27 n28 n29 n30 n31 n32 n33 n34 n35 n36
D n37 n38 n39 n40 n41 n42 n43 n44 n45 n46 n47 n48
E n49 n50 n51 n52 n53 n54 n55 n56 n57 n58 n59 n60
F n61 n62 n63 n64 n65 n66 n67 n68 n69 n70 n71 n72
G n73 n74 n75 n76 n77 n78 n79 n80 n81 n82 n83 n84
H n85 n86 Rapamycin Torin1 Thapsigargin Tunicamycin Brefeldin A Crizotinib R Ctr MEDIUM Ctr H2O Ctr DMSO Ctr
384 well treatment plate




Figure 1a. Human osteosarcoma U2OS GFP-LC3 cells and U2OS wt cells were treated with a library 
of bacterial metabolites for 6 h (compounds are listed in Appendix Table 1). After the treatment U2OS 
GFP-LC3 cells were fixed while U2OS wt cells were stained with Hoechst and PI for the cell death 
essay. GFP-LC3 dots were counted to measure autophagy activity. Scatter plots depicting the relative 


























































































































































































































































































































Figure 1b. Human osteosarcoma U2OS GFP-LC3 cells and U2OS wt cells were treated with a library 
of bacterial metabolites for 6 h (compounds are listed in Appendix Table 1). After the treatment U2OS 
GFP-LC3 cells were stained with DAPI and fixed, while U2OS wt cells were stained with Hoechst and 
PI for the cell death essay. GFP-LC3 dots were counted to measure autophagy activity. Scatter plots 













































































































































































































































































































































































































































We then rescreened the hits with the U2OS GFP-LC3 (for a third time) Fig 1c and with U2OS 
GFP‐RFP-LC3 tandem reporter cells to deeper investigate their activity on the autophagic flux. 
Fig 1d-e  
 
Figure 1c. Detection of GFP-LC3 puncta from compound-mediated autophagy in U2OS GFP-LC3 
cells. Human osteosarcoma U2OS GFP-LC3 cells were treated with the hits compound of the previous 
screening. After the treatment U2OS GFP-LC3 cells were stained fixed. GFP-LC3 dots were counted 









































































































































































































































































































































































































































































































































































































































































Figure 1d. Human osteosarcoma U2OS GFP-LC3 cells were treated with the hits compound of the 
previous screening. After the treatment U2OS GFP-LC3 cells were stained fixed. GFP-LC3 dots were 
counted to measure autophagy activity. Scatter plots depicting the relative healthy cell count versus the 








































































































Figure 1e. Human osteosarcoma U2OS RFP-GFP-LC3 tandem report cells were treated with the hits 
compound of the previous screening. After the treatment U2OS RFP-GFP-LC3 cells were stained fixed. 
GFP-LC3 and RFP-LC3 dots were counted to measure autophagy activity. Scatter plots depicting the 
















































Given the pronounced activity of this compound even at low concentration we selected 
prodigiosin from our screen. The pattern of GFP fluorescence induced by prodigiosin was 
slightly different from that induced by torin1. The GFP-LC3 puncta tended to fuse at one 
district around the nucleus. We decided to further investigate on this compound.  
We repeated the experiment on U2OS GFP‐RFP-LC3 tandem reporter cells for Prodigiosin 
and violacein. In U2OS cells stable expressing a tandem GFP-RFP-LC3 fusion protein 285, 
prodigiosin increased the abundance of the autophagosomes (RFP and GFP fluorescence) but 
not the autolysosomes (RFP fluorescence only), partially contrasting with the autophagic flux 
inhibitors bafilomycin A1 (BafA1), which induced an increase of GFP fluorescence by 
interfering with the autolysosome generation. Fig 1f and Fig 1g 
 
Figure 1f. Representative images of U2OS LC3 GFP-RFP tandem report cell treated with prodigiosin 
(Prod.) 0.5μM, bafilomycin A1 (BafA1) 0.1μM, and controls. 




Figure 1g. Human osteosarcoma U2OS RFP-GFP-LC3 tandem report cells were treated with the hits 
compound of the previous screening. After the treatment U2OS RFP-GFP-LC3 cells were stained fixed. 
GFP-LC3 and RFP-LC3 dots were counted to measure autophagy activity. Scatter plots depicting the 




























































As mentioned above, prodigiosin can cross the lysosomal membrane, reach its protonated 
configuration due to the high intralysosomal H+ concentration and export a Cl- ion from the 
lysosome to the cytosol together with three H+. Inducing de-acidification of the lysosomes it 
acts as an autophagy disruptor. 72. 
We then evaluated the effect of prodigiosin cotreating cell with the inhibitor of protein 
synthesis cycloheximide (CHX) and the RNA synthesis inhibitor actinomycin D (ActD), and 
with the V-ATPase and autophagic flux blocker bafilomycin A1 (BafA1). Cycloheximide 
(CHX) and Actinomycin D (ActD) did not prevent the induction of GFP-LC3 dots by 




Figure 2a. Representative images of U2OS GFP cell treated with prodigiosin (Prod.) 0.5μM and 1.5μM 















Figure 2b. Representative images of U2OS GFP cell treated with prodigiosin (Prod.) 0.5μM and 1.5μM 
alone or in combination with bafilomycin A1 (BafA1) 0.1μM. 






















































































































































































































































































































































































































































































































































































































Figure 2c. Bar chart. Data are expressed as means ± SD of one representative experiment and represent 
the GFP dots surface per cell, the GFP dots counts per cell, the DD and the cell count. (*p < 0.05, ***p 
























In this condition we did not observed the fluorescence pattern induced by Prodigiosin alone. 
We hypothesize that the blocking of the V-ATPase by BafA1 results in impaired concentration 
of H+ within the lysosome and consequently lysosomal alkalinization. In this context 
Prodigiosin cannot act as H+/Cl- symporter from the lysosome to the cytosol. Conversely, 
treating the cell with Prodigiosin for 3h at first and then, after changing the culture medium, 
with BafA1 for other 3h we observed that the florescence phenotype induced by prodigiosin 
seem to reverse. Fig 2d-e 
 
 
Figure 2d. Representative images of U2OS GFP cell after treatment with prodigiosin (Prod.)1.5μM 
and Bafilomycin (BafA1) 0.1μM for 3 hours followed by other 3 hours of switched treatment with 
Bafilomycin (BafA1) 0.1μM and prodigiosin (Prod.)1.5μM, respectively. 
3h
Prod. 1.5μM  
BafA1 0.1μM 
BafA1 0.1μM 



































































































































































































































































































































































































































Figure 2e. Bar chart. Data are expressed as means ± SD of one representative experiment and represent 
the GFP dots surface per cell, the GFP dots counts per cell, the DD and the cell count. (*p < 0.05, ***p 























Through the PC12 GFP-Q74 model we confirmed that our selected compound, the prodigiosin, 
seems to disrupt the autophagic machinery rather instead to boost it. In PC12 neuronal cells 
expressing a doxycycline-inducible autophagic cargo tagged with GFP (more in detail a GFP-
tagged pathogenic huntingtin protein holding 74 glutamine repeats, Q74) prodigiosin, 
contrasting with the activity of positive controls (torin1 and rapamycin), increased the green 
florescence thus suggesting an accumulation of the autophagic substrate. Fig 3a-c 
This evidence is consistent with an impairment of the autophagic flux. 
 
 
Figure 3a. Design of the experiment 
 
 
Figure 3b. Representative images of PC12 GFP-Q74 cell after 6 hours treatment with prodigiosin (0.06, 
0.2 and 0.5μM), rapamycin (Rapa, 20μM) and torin1 (Torin) 0.3μM.  
Pre-treatment with
Doxycycline (1 μg/ml) 
Discard and 



















Figure 3c. Bar chart. Data are expressed as means ± SD of one representative experiment and represent 
























































































































2.3.2 Prodigiosin induces a dose-depended increase of LC3-II and sequestosome 1 
 
Prodigiosin induced a dose-dependent increase in LC3 lipidation (detectable as an 
intensification of the LC3-II electrophoretic band). Concurrently an increase in the abundance 
of Sequestosome 1 (SQSTM1 or p62) protein level has been revealed. Fig 4a and 4b 
 
Figure 4 a-b. U2OS wild-type (WT) cells were treated with Prodigiosin (0.06, 0.2, 0.5 and 1.5μM) and 
torin (0.3 μM) for 6h. SDS–PAGE and immunoblots were conducted as described before. b. 
Immunoblot analysis of LC3 and p62 protein expression levels after 6-hour treatments. Band intensities 
of LC3-II, p62 and actin were assessed, and their ratios (LC3-II/actin) and (p62/actin) were calculated. 


























































































































2.3.4 Implication of TFEB in prodigiosin-induced autophagy modifications 
 
We described the activity of prodigiosin in inducing the transcription factor EB (TFEB) 
translocation in the nucleus using U2OS cells stably expressing GFP fused to TFEB. TFEB is 
known to promote the lysosomal biogenesis 56  
Interestingly, we found that this compound was able to induce the translocation of GFP-TFEB 
from the cytoplasm to the nucleus. Fig 4c-d  
Probably this event may be attributable to the activity of prodigiosin analogues in inhibiting 
mTORC1 and mTORC2 complexes. 286 The inhibition of mTORC1 has been already described 
as a trigger of TFEB activation. 59 
We interpreted this evidence as a prodigiosin-mediated stimulus to the lysosomal genesis while 
standing a subsequent block to the autophagic flux. Furthermore, this could be speculatively 
consistent with the scope of S. marcescens to create intracellular niches where housing. 
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Figure 4 c-d. Prodigiosin induces TFEB translocation in the nucleus: static images and quantification. 
c. Representative images of U2OS GFP-TFEB treated with Prodigiosin (0.2, 0.5 and 1.5μM) and Torin 
(0.3, 0.5 and 1μM) as controls for 6h.  d. The average ratio between GFP-TFEB florescence intensity 
in the nucleus versus the cytoplasm is reported in the bar chart.  Data are expressed as means ± SEM of 
at least three independent wells from one of three independent experiment (*p < 0.05, **p <0.01, ***p 



























































2.3.5 Colocalization of prodigiosin with lysosomes and other organelles 
 
We took advantage of the prodigiosin autofluorescence to find where it localizes inside the 
cells by matching its red fluorescence with the green fluorescence of the biosensor cell lines or 
fluorescent antibody staining. As showed by the merged images the green (GFP) and red 
(Prodigiosin) fluorescence remarkably seem to overlap in the Golgi apparatus and in the 



































































































































































































































2.3.6 Prodigiosin seems to impair the efficacy of anticancer immunotherapy. 
 
In light of its potential and previous literature on the immunosuppressive activity of 
Prodigiosines we evaluated the activity of this compound in vivo to address its potential in 
modifying the tumor growth and the response to anti-PD-1 ICB. BALC/c female were treated 
according the scheme reported in Figure 6a with isotype control, clone 2A3, plus prodigiosin 
vehicle (controls); anti-PD-1 mAb (250µg/mouse; clone RMP1-14) plus vehicle; Prodigiosin 
plus isotype control; Prodigiosin plus anti-PD-1 mAb; anti-PD1 plus anti-CTLA-4 (100µg of 
anti-CTLA-4 mAb (clone 9D9).  We observed that prodigiosin seems to promote the tumor 
growth (statistical significance not reached). Furthermore, the tumor growth was significantly 
higher in the group treated with prodigiosin plus anti-PD-1 as compared to the group treated 
with anti-PD-1 alone (mean tumor size: 45.2 vs 28.6 mm², respectively; p<0.05 by Anova 
statistics with Bonferroni post hoc test). Fig. 6b  




Figure 6 a-b. Prodigiosin seems to impair the efficacy of anticancer immunotherapy. a design of the 
experiment. b. variation in tumor volume after 2 days from the treatment administration. Tumor size 
differences were calculated either using two-way analysis of variance (ANOVA) and post hoc T-test 
with Bonferroni Correction (to compare the group treated with Prodigiosin plus Anti-PD-1 mAb versus 
Anti-PD-1 mAb alone: *p < 0.05, **p <0.01, ***p < 0.0001). 
To date only one experiment has been performed.  
 
BALB/c mice - CT26 cell line














































a) Ctrl (ISO + vehicle)4 x
b) Anti-PD-1 (+ vehicle) 5 x
c) Prodigiosin (+ ISO)5 x
d) Prodigiosin + Anti PD-1  5 x
Fig 6b
Fig 6a













2.4 Discussion and future perspectives  
 
Autophagy plays a cardinal and double-edge role during tumorigenesis. On the one hand, this 
catabolic mechanism acts as a tumor suppressor by removing oncogenic components. On the 
other hand, autophagy helps cancer cells survive by supporting their metabolic needs in a 
nutrient-deprived and hypoxic microenvironment. 287 The role of certain compounds in 
modulating anti-cancer immunosurveillance by targeting autophagy has recently emerged. 288 
However, the pleiotropic activity of certain systemic-administered molecules could deserve a 
double look, particularly regarding potential bystander effects on immune cells. 289 
Pharmacological autophagy inducers, as well as some lysosomotropic agents, have been shown 
to enhance anti-cancer immunosurveillance, potentiate immune checkpoint blockade 
treatment, and perhaps overcome chemoresistance, according to recent findings. 69 290 291 292 
From our screen on bacterial and host metabolites, we selected prodigiosin for its prominent 
activity in inducing LC3 dots, even at low concentrations. This compound is already known 
for its potential to induce apoptosis of leukemic and other malignant cells as well as for its 
immunosuppressive properties. 
In the present study, we further report that prodigiosin, a red metabolite produced by some 
strains of S. marcescens and other Gram-negative bacteria, is a potential disruptor of the 
autophagic machinery and probably hinders the efficacy of anti-PD-1 mAbs in the CT26-
BALB/c mouse model. This evidence, if confirmed by replicative experiments in vivo and 
retrospective clinical evidence, could open a scenario on the plausible activity of this bacterial 
metabolite as a disruptor of immunotherapy efficacy. 
In light of these results, two main perspectives remain open and could deserve attention.  
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The first, mainly clinical, is the investigation of the effect of immunotherapies in patients with 
concomitant opportunistic infection sustained by prodigiosin-producing bacteria. A research 
article published on NEJM in 2003 shed light on the relevance of S. Marcescens contamination 
in bronchoscopes. 197 Other previous studies depicted this bacterium as frequently involved in 
nosocomial infections. In light of the immunomodulatory activities of prodigiosin (especially 
the effect on cytotoxic CD8+ T lymphocytes) and the preliminary results of our experiment in 
vivo (Fig 6a – it requires confirmation) further investigation could be justified.  
A starting point could be the assessment of the efficacy of immunotherapy in a retrospective 
series of patients with lung or urothelial cancer and concomitant opportunistic infections 
sustained by S. Marcescens.  
The second, which mainly relies on the results of the experiment in combination with 
Bafilomycin (Fig 2 b-e) and on a previous research published on Chem 72, concerns the 
evaluation of the lysosome deacidification (and of the concomitant cytosolic acidification) as 
a potential player in reversing the canonical trafficking of autophago-lysosomes from 
endoplasmic reticulum to the cellular membrane.  
Some previous reports have shown how the cell precisely regulates the intracellular pH. As an 
example, histone deacetylases can induce histone deacetylation in a condition of decreased pH. 
293 This phenomenon results in the release of acetate anions which in turn were co-exported 
coupled with protons out of the cell at the hand of monocarboxylate transporters (MCTs). 293 
Viceversa in presence of increased pH, histones are acetylated. 293 Now, the role of protein 
deacetylation in inducing autophagy is clear and mentioned above.  
On account of that and other pieces of evidence, the intracellular-pH decrease could indirectly 
act as autophagy inducers. This hypothesis could open a new interesting scenario on the role 
of the intracellular pH decrease as an independent inducer of autophagy.  
Furthermore, evidence of defective autophagy in cancer cells is already known. Conversely, 
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from the tumor microenvironment, which exhibits an acidic pH, the intracellular pH of 
malignant cells is increased. 294 295 This evidence is consistent with the anabolic status of 
malignant cells, and with the observation of an increased pH in replicating cells. The pH is “de 
facto” one master regulator of autophagy.  
In such a context, the role of anion transporters, as our hit, prodigiosin, can gain attention when 
viewed from a different perspective. Worthy of note is the evidence that the protonophore 
FCCP, a mitochondrial uncoupler, is able to induce mitophagy at the concentration of 10μm 
through cytosol acidification rather than mitochondrial depolarization. 39  
As a result of our experiment and previous literature, we could state that prodigiosin probably 
induces autophagy (possibly inducing a decrease in cytosolic  pH) 296 as suggested by the TFEB 
translocation into the nucleus, but in the meantime hinders the autophagic flux (by inducing 
the alkalinization of lysosomes).   
In conclusion, prodigiosin acts primarily as an uncoupler of the pH gradient between the 
lysosomes and the cytosol. 72 This latter evidence could be further confirmed by visualizing 
the intracellular proton flux. 297 Furthermore, this compound is able of inducing death by 
apoptosis of the malignant cell 202 204, but its effect on the autophagic flux and its activity as an 
immunosuppressive agent could result in impaired efficacy of immunotherapy. 
  
 80 
2.5 Key words and Abbreviations 
 
Key words: bacterial metabolites; prodigiosin; immune modulators; immune checkpoint 
blockers; immunogenic cell death, intracellular pH. 
 
List of abbreviations: 
 
ActD actinomycin D  
anti-PD-1 mAb anti-PD-1 monoclonal antibody 
anti-CTLA-4 anti-CTLA-4 monoclonal antibody 
BafA1 bafilomycin A1 
CHX cycloheximide  
ER Endoplasmic reticulum 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor  
 
IC50 inhibitory concentration 50 
 
LC3 light chain 3 
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